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MaOBJECTIVES This study provides preliminary data on the safety and feasibility of the use of a novel focal implant for
managing post–percutaneous transluminal balloon angioplasty (post-PTA) dissection.
BACKGROUND Post-PTA dissection of the lower extremity arteries is managed with stent placement. This provides
anacceptablepost-intervention result buthas long-termdisadvantages, suchas in-stent restenosis. Focal treatmentofpost-
PTA dissection and avoidance of stents are the objectives of the Tack-It (Intact Vascular, Inc., Wayne, Pennsylvania) device.
METHODS A preclinical study and ﬁrst-in-human data are presented. Seven swine underwent superﬁcial femoral artery
device placement, with a self-expanding nitinol stent on 1 side and a series of 4 Tack-It devices on the other side.
Specimens were harvested at 28 days. The clinical study included 15 limbs that underwent revascularization for critical
limb ischemia (n ¼ 9) or claudication (n ¼ 6). Twenty-ﬁve lesions were treated in the superﬁcial femoral (n¼ 8), popliteal
(n ¼ 7), and tibial (n ¼ 10) arteries.
RESULTS The preclinical study demonstrated a reduction in stenosis with the Tack-It (16.8  2.6%) compared with
stents (46.4  9.8%). Neointimal thickness and injury score decreased with the Tack-It. Clinically, Tack-It placement
resulted in acute technical success with resolution of the post-PTA dissection in 100% of lesions. There were no device-
related complications or major amputations. Eighteen of the 25 lesions were available for angiographic follow-up at
1-year, and patency was 83.3%.
CONCLUSIONS Preclinical data suggest that the Tack-It device causes minimal vessel injury. Clinical use of the Tack-It to
manage post-PTA dissection was safe and feasible in this early study and resulted in apposition of dissection ﬂaps without
stent placement. (J Am Coll Cardiol Intv 2015;8:347–54) © 2015 by the American College of Cardiology Foundation.T he existing paradigm for managing lower ex-tremity occlusive lesions is severely limitedby currently available tools. Balloon angio-
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348require mechanical support with stent
placement. Unfortunately, stents induce
chronic injury and underlying inﬂamma-
tion, leading to intimal hyperplasia forma-
tion and in-stent restenosis (5–7). Stent
fracture is the consequence of implanting
relatively rigid metal scaffolds in areas
exposed to complex biomechanical forces,leading to the continuous and unrelenting deforma-
tion of the stent within the vessel (8,9).
These untoward clinical outcomes have motivated
investigators to seek alternative solutions that pro-
vide the beneﬁts of scaffolding but aim to induce low
levels of inﬂammation and neointimal hyperplasia. It
has been proposed that treatment with a minimal
implant aimed at providing focal tissue apposition and
ﬁxation of dissection ﬂaps would provide a smooth
arterial ﬂow surface without the long-term disadvan-
tages imposed by a stent. The Tack-It device (Intact
Vascular, Inc., Wayne, Pennsylvania) provides focal
mechanical support only where needed after PTA. This
is an opportunity to achieve an acute stentlike angio-
graphic result without a stent. The technology func-
tions on the basis of less metal, less outward force,
minimal scaffolding, spot treatment, and an oppor-
tunity for more natural remodeling of the treated
lesion while maintaining arterial ﬂexibility.
METHODS
EXPERIMENTAL PROTOCOL. A total of 7 healthy
swine received bilateral superﬁcial femoral artery
(SFA) implants and were kept alive for 28 days. At the
time of the implantation, 1 SFA underwent deploy-
ment of a series of 4 (each 6 mm in length) nitinol self-
expanding Tack-It devices. The contralateral artery
received a self-expanding nitinol stent (40 mm long
SMART stent [Cordis Corporation, Fremont, Califor-
nia) as a control. Fourteen vessels were explanted at 28
days and submitted for light microscopy and mor-
phometric analysis. Animal investigation included
animal care and use by qualiﬁed individuals, super-
vised by veterinarians, and facilities and transpor-
tation complying with legal requirements and
guidelines; anesthesia was used for all interventions,
and animal facilitiesmet the standards of the American
Association for Accreditation of Laboratory Animal
Care.
LIGHT MICROSCOPY PROTOCOL. Explanted vessels
were dehydrated in a graded series of ethanol solutions
and embedded in methyl methacrylate plastic. After
polymerization, each Tack-It device was sawed at 3
levels, and each stent was sawed at 4 levels. All seg-
ments were glued onto plastic slides and ground to athickness of 17 to 70 mm using Exakt Linear Grinding
technology (EXAKT Technologies, Inc., Oklahoma
City, Oklahoma). All sections were examined by light
microscopy for the presence of inﬂammation,
thrombus, neointimal formation, and vessel wall
injury. Histologic sections were analyzed using digital
planimetry with a calibrated microscope system (IP
Lab Software, Rockville, Maryland). Cross-sectional
areas of the vessel, stent, and lumen were analyzed
using conventional and previously published for-
mulas. In addition, vessel healing was analyzed by
quantifying strut apposition, ﬁbrin deposition, gran-
uloma and giant cell reactions, hemorrhage around the
device struts, and total number of uncovered struts.
PATIENT POPULATION AND STUDY DESIGN. The
clinical study was a prospective, nonrandomized,
ﬁrst-in-human safety and feasibility study with
1-year follow-up, registered at ClinicalTrials.gov
(NCT02044003). Patients were treated at 2 sites in
Asunción, Paraguay (Santa Clara Hospital and The
Italian Hospital). Eleven patients were enrolled
(15 lower extremities treated). Seven patients under-
went treatment of 1 lower extremity, and 4 patients
underwent treatment in both legs. The protocol was
approved by the Human Subjects and Ethics Commit-
tee of each hospital. Major adverse events (MAEs) were
reviewed by an independent clinical events commit-
tee. The subjects’ written informed consent was ob-
tained. Baseline clinical data were collected on case
report forms by a clinical research coordinator at the
study sites. A database of patients and dissections was
maintained. Data management was performed by
Northwest Clinical Research Group, Inc. (Woodinville,
Washington). The database was built on Microsoft
Excel, and the data were audited by Databent (Seattle,
Washington). The safety endpoint was the MAE rate,
deﬁned as the composite of death, device emboliza-
tion, the occurrence of surgery related to the device,
device-related occlusion of the artery, or major un-
planned amputation of the ipsilateral lower extremity
at 30 days. The feasibility endpoint was the ability to
secure vascular dissection ﬂaps with the device at
the time of implantation. The technical success
endpoint was deﬁned as acute luminal patency at
the conclusion of the revascularization procedure,
with angiography demonstrating that the lumen of
the artery at the location of implant remains patent.
Patients were followed at 1 month, 6 months, and
12 months with clinical examination. One-year
angiographic follow-up was obtained. Restenosis
was deﬁned as $50% by angiography.
TACK-IT DEVICE AND PLACEMENT PROCEDURE.
Each patient underwent angiography to assess lower
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349extremity lesions. Heparin was administered, and
transfemoral sheath placement was performed, using
either up-and-over or antegrade approach using a 6-
French access sheath. Heavily calciﬁed lesions were
excluded from the study (deﬁned as circumferential
calciﬁcation or contiguous calciﬁcation of $4 cm
along the length of the lesion). The lesion was crossed
using a standard guidewire technique. Each patient
underwent balloon angioplasty with the balloon
inﬂated to nominal pressure to match the reference
vessel diameter. Post-PTA angiograms were obtained
in multiple views. Any signiﬁcant residual stenosis
($30%) was treated with repeat PTA. Post-PTA
dissection ﬂaps were identiﬁed. The Tack-It delivery
catheter was loaded onto the same guidewire and
advanced to the site of the post-PTA dissection. The
tacks were deployed separately at intervals of $6 mm
from each other across the lesion. Each tack has an
axial length of 6 mm (Figure 1) (10). The Tack-It is a
self-expanding nitinol device that is speciﬁcally
designed for tissue apposition and focal pressure
application. Tack-It device features include low out-
ward force, paired anchor ﬁxation barbs in the center
of the implants, and variable pressure application,
with more pressure exerted by the middle section of
the device than by the wings. The device has a rela-
tively ﬂat outward force curve, so there is minimal
change in outward force when implanted in vesselsFIGURE 1 The Tack-It Device Is Indicated for the Focal Treatment o
The Tack-It device is a self-expanding nitinol design that is 6 mm in len
from 2.5 mm to 5.5 mm. The device is secured by 6 pairs of anchor ﬁxa
a radiopaque (RO) marker for radiographic visualization of the device.over range of diameters of several millimeters. The
unconstrained diameter of the device is 7.3 mm. It
is indicated for vessels with a reference diameter
ranging from 2.5 to 5.5 mm. This permits serial im-
plantation of the devices into a tapering artery
without signiﬁcant change in the mechanism and
function of the device and without exerting increased
outward force. The outward force exerted by the tack
is lower than that observed in commercially available
lower extremity stents. After deployment across the
dissected segment, post-placement balloon angio-
plasty is performed to secure the device and the
anchor ﬁxation barbs. Follow-up catheter-based
angiography was performed in all available patients
after 12 months or sooner if repeat revascularization
was required.
RESULTS
EXPERIMENTAL STUDY. All implanted animals sur-
vived the entire in-life duration. Both devices
matched vessel anatomy with good apposition (<5%
malapposed struts in both groups). The percent
of diameter stenosis was reduced (16.82  2.64%) in
the Tack-It group compared with the stent group
(46.37  9.75%). Neointimal growth consisted of
organizing smooth muscle cells in a proteoglycan
matrix, and it was higher in the stent group (Figure 2).f Post-PTA Dissection
gth and is able to treat arteries over a 3-mm range of diameters,
tion features that are located in the center of the Tack-It, each with
FIGURE 2 Histology Specimens Were Obtained From the Proximal, Mid-, and Distal Segments of the Implants
The Tack-It device has lower outward force and stimulated less neointimal response. The stent is able to create a larger lumen with higher outward force but stimulates
signiﬁcant neointimal hyperplasia.
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350Peristrut ﬁbrin deposits were minimal in the Tack-It
group and occurred in 11.01  11.10% of the struts,
whereas they were greater and more frequently seen
(48.14  14.61%) in the stent group. The Tack-It group
demonstrated lower injury scores, less inﬂammation,
and more endothelialization than the stent group.
Histological parameters are summarized in Table 1.
EARLY HUMAN CLINICAL STUDY. The mean age of
the 11 enrolled patients was 66 years (range 47 to 85
years). Five of the 11 (45%) were male. All patients
had a history of hypertension (11 of 11), hyperlipid-
emia was present in 72.7% (8 of 11), and coronary
artery disease was present in 72.7% (8 of 11). The
indication for revascularization in the 15 limbs ac-
cording to the Rutherford classiﬁcation was gangrene
(stage 5) in 5 patients, rest pain (stage 4) in 4, and
claudication (stage 3) in 6. Of the 15 limbs, there were25 treated lesions of the SFA (n ¼ 8), popliteal artery
(n ¼ 7), and tibial artery (n ¼ 10). Six of the 25 lesions
(24%) were occlusions, and 19 were stenoses. Among
the 6 occlusions, 5 were crossed using a looped sub-
intimal wire, and 1 was crossed transluminally. The
mean lesion length was 5.6  4.2 cm. Acute technical
success was achieved with Tack-It placement and
tissue apposition/ﬂap management in 25 of 25 treated
arteries (100%), as determined by completion angi-
ography (Figure 3). In each case, the area of dissection
was successfully tacked down, and no dissection ﬂaps
persisted. The safety, feasibility, and technical end-
points are summarized in Table 2. The number of
Tack-It devices placed per patient ranged from 1 to 12
(mean 3.4). Forty-eight of 50 devices were placed
accurately (96%). In 1 case, 2 Tack-It devices were
placed imprecisely near, but not at, the intended
target (reference vessel diameter, 5.2 mm). Additional
TABLE 1 Comparison of Self-Expanding Nitinol Stent and
Tack-It Device
Tack-It Implant
Group
(n ¼ 28)*
Implant Group
Stent
(n ¼ 7)
Implant
Group
p Value
EEL area, mm2 11.85  1.38 19.63  1.63 <0.0001
IEL area, mm2 9.91  1.29 17.27  1.29 <0.0001
Lumen area, mm2 8.22  1.11 8.85  1.87 0.269
Medial area, mm2 1.94  0.34 2.35  0.79 0.0232
Strut malapposition, % 4.14  8.68 4.17  7.22 0.994
Struts with ﬁbrin, % 11.01  11.10 48.14  14.61 <0.0001
Struts with giant cells, % 0.33  0.89 0.10  0.27 0.497
Struts with RBCs, % 10.29  7.06 44.38  9.21 <0.0001
Endothelialization, % 99.28  2.50 96.79  3.01 0.0355
Uncovered struts, % 1.56  7.14 5.48  6.21 0.209
Mean injury score 0.12  0.069 0.44  0.24 <0.0001
Mean ﬁbrin score 0.25  0.31 1.25  0.20 <0.0001
Neointimal inﬂammation
score
0.11  0.20 0.57  0.28 <0.0001
Adventitial inﬂammation
score
0.00  0.00 0.14  0.20 0.0004
Values are mean  SD. *Animal 16-106D (CV29819) RSFA Tack 1 mid-section
excluded from analysis due to processing artifacts, and a section was un-
available from the proximal region of animal 16-117D (CV29821) RSFA
Tack 4.
EEL ¼ external elastic lamina; IEL ¼ internal elastic lamina; RBCs ¼ red blood
cells.
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351Tack-It devices were implanted, and there were no
untoward consequences. Of the 15 lesions of the su-
perﬁcial femoral and popliteal arteries, there were 5
occlusions (33%), and of the 10 lesions of the tibial
arteries, there was 1 occlusion (10%). The number of
Tack-It devices implanted in the femoral-popliteal
lesions ranged from 1 to 5, and in the tibial lesions,
it ranged from 1 to 3. The mean procedure time was 51
min (range 10 to 128 min). The mean ﬂuoroscopy time
was 13 min (range 5 to 30 min).
One patient had an intraprocedure puncture site
thrombosis (contralateral femoral area using up-and-
over approach) that required thrombus aspiration.
One patient died of a myocardial infarction in the
perioperative period. The MAE rate was 9.1% (1/11) due
to the death in the perioperative period. Two patients
were lost to follow-up before 1 year. There was no
occurrence of device embolization, surgery related to
the device, device-related occlusion of the artery, or
major amputation. Eighteen of the 25 lesions were
available for follow-up at 1 year, and angiographic
patency was 83.3%. There was recurrent stenosis
($50%) in 3 of 18 (16.7%). One patient with a popliteal
artery occlusion and toe gangrene underwent recana-
lization, balloon angioplasty, and Tack-It placement
but returned with a recurrent stenosis as seen on
duplex ultrasonography at 3 months and required
repeat angioplasty and Tack-It placement for a targetlesion revascularization rate of 4%. The 1-year patency
rate for the femoral and popliteal artery lesions was
87.5%. Recurrent stenosis developed in 2 patients with
tibial artery lesions, for a 1-year tibial artery patency
rate of 80%. One lesion recurred after treatment of an
occluded tibioperoneal trunk, and 1 occurred after
treatment of a stenosis. Both patients initially had
healed ischemic foot ulcers that healed and neither
required repeat intervention. The 1-year patency rate
for tibial artery lesions was 80%.
DISCUSSION
These preliminary results suggest that use of the Tack-
It device is safe and that this alternative nonstent
method of securing post-PTA dissection ﬂaps is
feasible. The experimental evaluation of the Tack-It
device at 28 days demonstrated less neointimal for-
mation, degree of injury, inﬂammation, and stenosis
than an SFA-approved self-expanding nitinol stent. In
addition, overall vascular healing was superior with
the Tack-It device as reﬂected by the lower amounts of
peristrut ﬁbrin and red blood cell deposits. The anchor
ﬁxation segment of the Tack-It device did not induce
additional degrees of inﬂammation.
The ﬁrst-in-human study demonstrated the feasi-
bility and safety of focal treatment of post-PTA
dissection in the lower extremity using a novel
implant designed to achieve tissue apposition but
maintaining the natural conﬁguration and qualities
of the artery. Multiple post-PTA dissections were
managed in a range of arteries and lesion morphol-
ogies without bailout stent placement. The 1-year
angiographic patency was acceptable in this small
preliminary study comprising all-comers: lesions of
the superﬁcial femoral, popliteal, and tibial arteries
and in limbs with gangrene, rest pain, or claudication.
The principles used in the construction of the Tack-It
device (less outward force, less metal, and spot treat-
ment) are speciﬁcally intended to address areas in
which currently available devices have failed (Table 3).
A much larger study is required to understand the
overall patency implications of this approach.
Balloon angioplasty plays a major role in lower
extremity revascularization and will likely be an
essential technique in the foreseeable future. Drug-
coated balloons have shown promise and will prompt
renewed interest in the angioplasty mechanism and
how it may be optimized (11–13). In arteries that are
obstructed by atherosclerotic plaque, balloon angio-
plasty increases the vessel lumen diameter by causing
dissection. Post-PTA dissections are uncontrolled
arterial injuries that are usually manifested by longi-
tudinal tears creating tissue ﬂaps of varying degrees of
FIGURE 3 A 65-Year-Old Man With Short-Distance Right Leg Claudication
(A) Angiogram of right superﬁcial femoral artery before treatment. (B) Post-angioplasty dissection (arrows). (C) Three Tack-It devices (arrows)
deployed in right superﬁcial femoral artery to treat post-angioplasty dissection. (D) Completion angiogram after Tack-It device placement.
(E) Angiogram performed in follow-up at 1 year.
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352severity that are visible angiographically. When post-
PTA dissection produces a suboptimal result in cur-
rent practice, the only reasonable option available is
stent placement to secure the dissection ﬂap and
ensure the integrity of the lumen. Contemporary SFA
stent trials conducted primarily in TASC A and B le-
sions have a stent bailout rate of 35% to 50% in patients
randomized to balloon angioplasty (14,15). The more
challenging lesions (TASC C and D, longer lesions,occlusions) are even more likely to require mechanical
support, and a stent is often deployed to achieve an
acceptable result (16–18). One major unsolved chal-
lenge is that it remains unclear which dissections
require treatment and which do not.
Almost every important aspect of stent design and
construction is associated in some way with stent
failure. For example, the stent material, degree of
outward force, wall pattern, rigidity, stent length, and
TABLE 3 Principles of Design of the Tack-It Device
Minimal Implant Low Outward Force Focal Treatment
Minimizes metal to
artery interface
Low outward force with minimal
inﬂammatory response
Treat multiple lesions/
dissections with 1 device
Maintain arterial ﬂexibility
minimizing device stress
Same outward force over
a range of diameters
Mechanically tacks down
dissection ﬂap to create
Allow artery to remodel in
more natural manner
Pressure exerted by
device at focal points
Smooth vessel wall surface
Tissue apposition
Stable deployment
TABLE 2 Perioperative and Long-Term Results of the
Tack-It Device
Technical success 100
Feasibility (ability to secure dissection ﬂaps) 100
Safety (rate of MAE) 9.1
Accuracy (ability to place Tack-It at the desired location) 96
12-month angiographic patency 83.3
12-month target lesion revascularization 4.0
Values are %.
MAE ¼ major adverse event.
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353strut thickness are all associated with in-stent reste-
nosis (16,19–24). It is apparent that the longer the
lesion is, the lower the long-term patency. This is
typically attributed to lesion length; however, it may
also be due to stent length, which becomes corre-
spondingly longer with lesion length. It is generally
agreed that a “full metal jacket” is not a durable or
desirable solution (25). This suggests that when me-
chanical support is required at the treatment site, one
consideration may be to minimize the implant.
The current treatment paradigm with balloon an-
gioplasty and stenting is somewhat inﬂexible and
indicates stent placement even when much less me-
chanical support and less metal may actually be
required. A stent is generally able to provide a smooth
post-intervention surface but may also provide too
much scaffolding, causing increased stiffening of a
highly mobile and ﬂexible artery. Stents may also
cover too much surface area with metal, apply too
much chronic outward force against the artery wall,
and allow too much friction between the metal
implant and the artery wall. In the interest of man-
aging post-PTA dissection, the function of a stent in
the current treatment paradigm is to force the artery
into a conﬁguration that it would not otherwise
naturally assume. Newer stents of various conﬁgura-
tions or that exert varying forces or are coated with
medication have been introduced, with each design
intended to minimize the impact of the implant on
the recipient artery (26). However, it is possible that
these constructs cause injury that exceeds the
acceptable threshold that might avoid the previously
mentioned stent-related failure modes. Substantial
arterial scaffolding with a stent permanently altersthe conformational quality of the artery. When in-
stent restenosis occurs, there is no durable treat-
ment (27,28). When the continuum of care is assessed
over the patient’s life span, the patient may be better
off without a stent in the lower extremity. When a
stent is placed, a bridge is burned along that care
continuum. Perhaps a stentlike acute angiographic
result could be achieved without the late complica-
tions of a stent. In addition, the availability of an
accurate method of spot treatment returns control of
the procedure to the operator. This increases preci-
sion, provides only as much mechanical support as is
needed, and is more akin to a dose-response approach
to optimizing balloon angioplasty.
Use of the Tack-It is a highly versatile solution to a
complex problem. This approach provides the ability
to treat a broad range of artery diameters with a single
device and to treat multiple locations with a single
catheter. Use of the Tack-It Endovascular Stapler to
manage post-PTA dissection is safe and feasible. It
resulted in less injury, inﬂammation, and stenosis
than standard control SFA stents in the pre-clinical
study and permanent securement of dissection ﬂaps
without stent placement and with reasonable angio-
graphic patency at 1 year in this ﬁrst-in-human study.
This device provides focal treatment of post-PTA
dissections, allowing the artery to maintain its natu-
ral conﬁguration, avoid overscaffolding with stents,
and potentially avoid the long-term failure modes of
in-stent restenosis and stent fracture.
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